Regulatory

Empower Pharmacy warning letter: what it means in 2026

The FDA warned Empower Pharmacy over compounded tirzepatide and semaglutide. What the letter says, whether compounded GLP-1s are still legal, and what to check.

SafePeptideUseSeptember 24, 20265 min read

Key takeaways

On September 18, 2026 the FDA sent a warning letter to Empower Pharmacy in Houston over compounded tirzepatide and semaglutide products it called essentially copies of approved drugs.
Inspectors also found gaps in how the pharmacy proved its sterile work areas stayed clean, which the FDA treats as insanitary conditions.
A warning letter is a formal notice, so nothing has been recalled or shut down yet. Empower has 15 working days to respond, and the FDA says unresolved violations can lead to seizure or an injunction.
The same week, a coalition of 20 state attorneys general warned federal officials about counterfeit GLP-1 ingredients coming out of China.
The letter describes weak contamination controls, and it does not report a confirmed contaminated batch. It is still a good moment to check exactly where your medicine comes from.

What did the FDA say about Empower Pharmacy?

The FDA says Empower Pharmacy was mass producing copies of approved tirzepatide and semaglutide and calling them personalized. The Empower Pharmacy warning letter, dated September 18, 2026, also says the Houston pharmacy could not show its sterile rooms were kept clean enough.

The letter follows an inspection that ran from November 3 to 14, 2025. It names three products: two tirzepatide and niacinamide injections and a semaglutide and cyanocobalamin (vitamin B12) injection. The agency wrote that these appeared to be "essentially copies" of the approved tirzepatide and semaglutide drugs.

We read the full letter so you do not have to. Two problems run through it. One is legal: how much Empower was and why. The other is about cleanliness: whether the pharmacy could prove its sterile process works. Both matter if you use compounded injections, from Empower or anyone else.

Sources:s1

Is compounded tirzepatide still legal?

Yes, in narrow cases. A state licensed pharmacy can still compound tirzepatide or semaglutide for an individual patient when the prescriber decides a change to the drug makes a significant difference for that patient. What a pharmacy cannot do is copy an approved drug "regularly or in inordinate amounts", which is the wording in section 503A of federal law.

The wider window closed in 2025. While these drugs were in shortage, the FDA let pharmacies make copies. After it declared the shortages over, the grace period for regular pharmacies (called 503A pharmacies) ended on February 18, 2025 for tirzepatide and April 22, 2025 for semaglutide. Large outsourcing facilities (503B) lost it on March 19, 2025 and May 22, 2025.

So a is legal only when it is truly made for you. We covered the parallel fight over research peptides in our FDA peptide compounding update.

Sources:s2, s3

Why did adding a vitamin not make it a different drug?

The FDA thinks the vitamin was there to get around the copy rule. Adding niacinamide or B12 to a is a common way compounders argue their product is different from the brand drug.

The letter pushes back hard. It says the volume Empower was producing "suggests that differences" between its products and the approved drugs "are pretextual", meaning an excuse. Inspectors also found prescriber notes justifying the change that appeared "repeated verbatim across many records", which reads like a template instead of a decision made for one person.

This is the part other compounders will study. Our read is that the FDA is saying a vitamin plus a form letter does not create a real clinical need.

Sources:s1, s2

Is compounded tirzepatide safe?

Warning

Nobody can say for certain, because nobody checks it the way approved drugs are checked. The FDA states plainly that drugs are not FDA approved and the agency "does not review compounded drugs for safety, effectiveness or quality" before they are sold.

The Empower letter shows why that matters for injections. Inspectors said the pharmacy did not run proper smoke studies to prove clean air flowed in one direction over its ISO 5 work area (the cleanest zone, where sterile vials are filled). They said its media fills, which are practice runs that check whether the process lets germs in, were not done under the hardest conditions. They also found weak monitoring of the rooms. None of this proves a vial was contaminated. It means the pharmacy could not prove its vials were safe from contamination, which is the whole job of sterile .

On the evidence side, the FDA has logged more than 215 adverse event reports tied to tirzepatide and more than 392 tied to compounded semaglutide, counted as of November 30, 2024. Treat those as anecdotal: they are unverified reports, and a report does not prove the drug caused the problem. The FDA has also reported adverse events, some needing hospital care, that may be related to dosing errors with compounded semaglutide.

The drugs themselves are well studied: approved tirzepatide and semaglutide rest on strong human evidence from large trials. What stays unknown with any version is whether the vial matches the label and was made cleanly. For more on the drugs, see our tirzepatide and semaglutide entries.

Sources:s1, s4

What are the attorneys general warning about?

They say counterfeit ingredients from China are reaching the American market. On September 18, 2026, Alabama Attorney General Steve Marshall announced a letter from a 20 state coalition to Secretary of State Marco Rubio and the National Security Council, and Tennessee described the same letter on September 23.

The coalition names a Chinese company, Harbin Jixianglong Biotech, that it says repackaged counterfeit semaglutide from an unapproved facility and altered manufacturing dates before shipping it to the United States. It says ingredients for semaglutide, tirzepatide and retatrutide are exposed, blames gaps in an FDA supplier program, and asks for tighter oversight.

That is an allegation in a letter, and no court has ruled on it. It still matters for anyone using or research GLP-1s, because the raw ingredient is where quality problems start. Retatrutide cannot be legally compounded at all, which we covered in our retatrutide 2026 update.

Sources:s5, s6, s4

Has Empower been warned before?

Yes. Endpoints News reports this is the third FDA warning letter for the pharmacy. Separately, in 2025 FiercePharma reported an FDA warning letter to Empower Pharma, a Houston outsourcing facility that Eli Lilly had sued for continuing to compound tirzepatide after the shortage ended.

A warning letter is a formal notice, and the FDA does not close a pharmacy with one. Empower has 15 working days to explain its fixes. The letter warns that failing to correct the violations "may result in legal action without further notice, including, without limitation, seizure and injunction." We found no public response from Empower by our publication date.

Sources:s7, s8, s1

What should you do if you use compounded GLP-1s?

Info

Start by finding out who actually makes your medicine. The pharmacy name is printed on the vial label and the shipping paperwork, even when a telehealth brand leaves it off its website.

A few questions worth asking your prescriber or telehealth service:

Which pharmacy compounds my prescription, and is it state licensed?
Why is my version different from the approved drug, and was that decided for me?
Can I see a for my batch? Our guide to reading a COA shows what a good one includes.
If my pharmacy stops making it, what is the plan so I do not run out suddenly?

Do not stop or switch a on your own because of this news. Talk it through with your clinician, who can weigh the approved versions, your cost and your history. If you inject at home, our injection technique guide covers clean handling, and redness, heat, swelling or fever after a shot are reasons to call a clinician promptly.

This is education, not medical advice.